Massive MS study tracks 10,500 patients for drug safety clues
NCT ID NCT05767736
First seen Nov 01, 2025 · Last updated May 22, 2026 · Updated 32 times
Summary
This study looks at the long-term safety of two MS drugs, Vumerity and Tecfidera, by analyzing data from over 10,500 patients in large registries. Researchers will track serious side effects like infections and cancer, comparing these drugs to other MS treatments. The goal is to better understand risks, not to test a new treatment.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MULTIPLE SCLEROSIS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Research Site
Cambridge, Massachusetts, 02142, United States
Conditions
Explore the condition pages connected to this study.